Filter By
Search
-
FIRST-HALF 2023 SALES OF €5.6 M, DOWN 13 % ON S1 2022, AND CASH POSITION OF €4.3 M
EVRY, FRANCE, THURSDAY JULY 13TH 2023, 7:30 AM - IntegraGen (FR0010908723 - ALINT - PEA eligible...
-
FIRST-HALF 2023 RESULTS - SALES DOWN 13% AND RESILIENT PROFITABILITY
Evry, France, Thursday October 19, 2023, 5:45 pm - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), a...
-
INTEGRAGEN AND BIOASTER SIGN PARTNERSHIP AGREEMENT IN GENOMICS AND TRANSCRIPTOMICS
IntegraGen and BIOASTER have been collaborating for several years on genomic and transcriptomic analyses. Driven by...
-
INTEGRAGEN SUPPORTS THE ANTOINE LACASSAGNE CENTER IN NICE FOR A LARGE-SCALE RESEARCH PROJECT ON COLORECTAL CANCER PATIENTS
Founded in 1961, the Centre Antoine Lacassagne is one of 18 cancer centers...
-
NEW LOOK. NEW PORTFOLIO. NEW OPPORTUNITIES.
FOLLOWING ITS ACQUISITION BY ONCODNA, INTEGRAGEN HAS UNDERGONE A COMPLETE OVERHAUL AND IS NOW...
-
POTENTIAL INVOLVEMENT OF URINARY TRACT INFECTIONS IN THE DEVELOPMENT OF BLADDER CANCER
Uropathogenic E.coli induces DNA damage in the bladder As provider of the whole genome sequencing, IntegraGen...
-
NEW PERSPECTIVES IN THE DIAGNOSIS AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Myogenesis modelled by human pluripotent stem cells: a multi-omic study of Duchenne myopathy early onset...
-
BRIEF TECHNIQUE: LOW-PASS WHOLE GENOME SEQUENCING - GETTING MORE FROM LESS
LP-WGS analysis of liquid biopsies (ctDNA) for oncology applications Background Analysis of circulating tumor DNA...
-
ANNOUNCEMENT OF THE AVAILABILITY OF THE INFORMATION MEMORANDUM AND THE DOCUMENT "OTHER INFORMATION CONCERNING THE LEGAL, FINANCIAL AND ACCOUNTING CHARACTERISTICS" OF ONCODNA S.A.
This press release has been prepared and issued by OncoDNA S.A. pursuant to...
-
COMBINED GENERAL MEETING
IntegraGen's Combined Ordinary and Extraordinary General Meeting will be held on September 17 at 2 pm...
